Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 614 clinical trials
A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene (ALSpire)

Part 1: The primary objective is to evaluate the safety and tolerability of BIIB105 in participants with amyotrophic lateral sclerosis (ALS) or poly-CAG expansion (polyQ)-ALS. The secondary objectives are to assess the pharmacokinetic (PK) profile in serum and cerebrospinal fluid (CSF), and to evaluate the biomarker effect of BIIB105 in …

riluzole
superoxide dismutase
primary lateral sclerosis
platelet count
edaravone
  • 0 views
  • 23 Oct, 2022
  • 12 locations
Human-like Robotic Controllers for Enhanced Motor Learning (HRCEML)

participants, participants post-stroke, and participants with spinal cord injury (SCI).

stroke
injuries
spinal cord
Accepts healthy volunteers
chronic pain
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam (ASCEND)

The primary objective of this study is to evaluate motor function following treatment with HD nusinersen in participants with spinal muscular atrophy (SMA) previously treated with risdiplam. The secondary objective of this study is to evaluate the safety and tolerability of HD nusinersen in participants with SMA previously treated with …

nusinersen
gene deletion
risdiplam
  • 0 views
  • 21 Oct, 2022
  • 12 locations
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Ambulant Patients With Spinal Muscular Atrophy

Risdiplam works by helping the body produce more survival motor neuron (SMN) protein throughout the body. This means fewer motor neurons - nerve cells that pass impulses from nerves to muscles to cause movement - are lost, which may improve how well muscles work in people with SMA. RO7204239 is …

nusinersen
risdiplam
corticosteroid
  • 0 views
  • 23 Oct, 2022
  • 8 locations
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis (ADORE)

Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.

weakness
primary lateral sclerosis
  • 1 views
  • 22 Oct, 2022
  • 26 locations
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.

riluzole
primary lateral sclerosis
assisted ventilation
edaravone
weakness
  • 0 views
  • 04 Oct, 2022
  • 9 locations
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA)

This is a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants,18 to 80 years of age with ALS followed by an openlabel, longterm extension period. Study ACT16970 consists …

riluzole
edaravone
primary lateral sclerosis
body mass index
  • 0 views
  • 07 Oct, 2022
  • 28 locations
A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)

The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.

riluzole
edaravone
weakness
primary lateral sclerosis
  • 0 views
  • 14 Oct, 2022
  • 55 locations
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (Phoenix)

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

riluzole
edaravone
treatment regimen
primary lateral sclerosis
  • 0 views
  • 27 Oct, 2022
  • 35 locations
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).

primary lateral sclerosis
cognitive impairment
amyotrophic lateral sclerosis
mini-mental state examination
dementia
  • 2 views
  • 01 May, 2022
  • 18 locations